No Data
No Data
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to Be Developed for Patients With Inflammatory Bowel Diseases
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)
Express News | Xencor Announces Upcoming Change to Board of Directors
Xencor Is Maintained at Outperform by RBC Capital
Xencor Analyst Ratings
No Data
No Data